TY - JOUR
T1 - New-onset Adult-onset Still’s disease-like syndrome after ChAdOx1 nCoV-19 vaccination—a case series with review of literature
AU - Padiyar, Shivraj
AU - Kamath, Navaneeth
AU - Mathew, John
AU - Chandu, A. S.
AU - Deodhar, Divya
AU - Shastry, B. A.
AU - Shashikala, T.
AU - Ganapati, Arvind
N1 - Funding Information:
We would like to thank Dr. Prabhu Vasanth for his contributions to the manuscript.
Publisher Copyright:
© 2022, International League of Associations for Rheumatology (ILAR).
PY - 2022/5
Y1 - 2022/5
N2 - We report a series of 3 Adult-onset Still’s disease (AOSD)-like presentations in previously healthy females following vaccination with the ChAdOx1 nCoV-19 vaccine, and also compare them with similar cases reported in literature through a PubMed database search. Our first patient had a high spiking bi-quotidian type of fever with myalgia, sore throat, and arthritis with onset 10-day post-vaccination, with laboratory features of hyper inflammation responding to only naproxen. She was off treatment after 2 months. The second patient, with onset 3-week post-vaccination, had a more severe illness, requiring high dose immunosuppression. In our third case, the onset of illness was slightly delayed i.e., 3-month post-vaccination, but she had the most severe disease with macrophage activation syndrome at presentation requiring immunosuppression and biologicals. The underlying mechanism may be linked to the activation of Toll-like receptors (TLR)—TLR-7 and TLR-9—leading to a robust immune response. These 3 cases highlight the immunogenicity of COVID-19 vaccines, with the possibility of occurrence of new-onset systemic hyper-inflammation illness which can happen a few days following the vaccination, sometimes even delayed to months, and can range in severity from mild to even life-threatening. More cases need to be studied to understand the profile and prognosis of these syndromes in the long run.
AB - We report a series of 3 Adult-onset Still’s disease (AOSD)-like presentations in previously healthy females following vaccination with the ChAdOx1 nCoV-19 vaccine, and also compare them with similar cases reported in literature through a PubMed database search. Our first patient had a high spiking bi-quotidian type of fever with myalgia, sore throat, and arthritis with onset 10-day post-vaccination, with laboratory features of hyper inflammation responding to only naproxen. She was off treatment after 2 months. The second patient, with onset 3-week post-vaccination, had a more severe illness, requiring high dose immunosuppression. In our third case, the onset of illness was slightly delayed i.e., 3-month post-vaccination, but she had the most severe disease with macrophage activation syndrome at presentation requiring immunosuppression and biologicals. The underlying mechanism may be linked to the activation of Toll-like receptors (TLR)—TLR-7 and TLR-9—leading to a robust immune response. These 3 cases highlight the immunogenicity of COVID-19 vaccines, with the possibility of occurrence of new-onset systemic hyper-inflammation illness which can happen a few days following the vaccination, sometimes even delayed to months, and can range in severity from mild to even life-threatening. More cases need to be studied to understand the profile and prognosis of these syndromes in the long run.
UR - http://www.scopus.com/inward/record.url?scp=85124147289&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124147289&partnerID=8YFLogxK
U2 - 10.1007/s10067-022-06065-7
DO - 10.1007/s10067-022-06065-7
M3 - Review article
C2 - 35041110
AN - SCOPUS:85124147289
SN - 0770-3198
VL - 41
SP - 1569
EP - 1575
JO - Clinical Rheumatology
JF - Clinical Rheumatology
IS - 5
ER -